Trial Profile
A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo in Postmenopausal Women With Osteoporosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary) ; Teriparatide
- Indications Postmenopausal osteoporosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Unigene Laboratories
- 11 Mar 2013 This study was the subject of an oral presentation at the 2012 Annual Meeting of the American Society of Bone and Mineral Research (ASBMR), according to a Unigene Laboratories media release.
- 01 Mar 2013 Results published in Bone.
- 12 Dec 2012 Full results have been published in BONE, the official Journal of the International Bone and Mineral Society, according to a Unigene media release.